Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis

Tregs is believed to provide a therapeutically effective dual mechanism of protection to patients treated with Tovaxin(TM). The observed regulatory immune responses have been shown to collectively correlate with clinical improvement in treated patients.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in a Phase IIb trial. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause Opexa Therapeutics' actual results to be materially different from any future results expressed or implied by such forward-looking statements. Opexa Ther
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:7/21/2014)... Oregon , July 21, 2014 ... Allied Market Research titled, "Global biosimilars/follow-on-biologics market (types, ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... the global biosimilars market would reach $35 billion ... 2013. Deeper penetration with clearer regulatory pathways in ...
(Date:7/21/2014)... 21, 2014 By order of the U.S. Bankruptcy ... sale of ophthalmic and optical equipment, designer eyeglass frames, and ... specialists American Optical Services LLC. Online bidding opens ... rapid succession, live auction style, on July 28 beginning at ... will be held July 25 th and 26 th ...
(Date:7/21/2014)... DENVER , July 21, 2014   Aventura ... and mobile applications, announced today that MemorialCare ... network, has successfully implemented its awareness computing solution at the ... View, California.  Orange Coast Memorial ... admitting more than 12,000 patients annually. The Aventura ...
Breaking Medicine Technology:Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 3Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 4Auction Set For Assets Of National Optical Services Company 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 3MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 4
... N.Y., Jan. 18 On January 17, 2008, the ... LLC, Douglas & London,P.C., Levin Simes Kaiser and Gornick ... have filed over a Billion ($1,000,000,000) Dollar,Class Action lawsuit ... Eastern District of New York, Docket #08-258 before The,Honorable ...
... Embryonic Stem Cell Lines for Therapeutic ... ... has,become the first to report, and painstakingly document, the cloning of a,human ... an,adult donor. The study was published online today by the journal "Stem,Cells.", ...
Cached Medicine Technology:Study Reports Successful Cloning of Human Embryo Using Adult DNA 2Study Reports Successful Cloning of Human Embryo Using Adult DNA 3
(Date:7/22/2014)... 2014 A new and technologically unique ... with results that are surprising even the most skeptical ... skin with radio frequency, ThermiTight has been dubbed “InjectableRF” ... the skin to “inject” heat to the tissues which ... single treatment solution for skin laxity produces results in ...
(Date:7/21/2014)... On Monday, September 22, 2014 Push to Walk will ... Solutions at The Knoll West Country Club, Knoll & Greenbank ... at 11 a.m. The price of $225 includes all ... $250 after September 7th. Non-golfers and guests are welcome ... dinner will include a special silent and live auction in ...
(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... It,s human nature to hate losing. , Unfortunately, ... potentially abandoning a solid strategy and thus increasing your ... one conclusion of a Brigham Young University study published ... The finding is based on an analysis of two ... researchers focused on whether coaches adjusted their personnel following ...
(Date:7/21/2014)... Center for Public Affairs Research has released the results ... what it means to be a quality health care ... the Robert Wood Johnson Foundation, sheds new light on ... care and doctors, as well as the information they ... survey produces new and actionable data during a crucial ...
Breaking Medicine News(10 mins):Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2
... of therapeutic agents that interferes with the ability of ... The results of the new study will be presented ... Meeting in San Francisco. , The cell-based study ... compounds are likely to be effective against breast cancers ...
... scientists work collaboratively, barriers of religion and ethnicity ... science to improve the lives of citizens worldwide. ... Gluck, professor of neuroscience at Rutgers University in ... after successfully organizing an international conference co-hosted by ...
... 16 Pittsburgh-based Foundation,Radiology Group (FRG) and Cherry ... which will make FRG the exclusive provider of,diagnostic ... Kishor E. Joshi, M.D., president of Cherry Tree ... Foundation Radiology Group. We expect,this partnership will enhance ...
... Association, a,regional non-profit established to foster relationships and ... announced today,the election of five new officers and ... New officers who were elected to serve a ... president, Aon Consulting; Past President - Thomas,Hoffman, partner, ...
... studies indicate that oral use of RU-486,s companion drug misoprostol ... , The off-label use of a drug given with RU-486 ... of rare, fatal infections seen in women taking the drugs ... , The drug misoprostol is FDA-approved to be taken ...
... & Lymphoma Society,s Light The Night(R) Walk Offers Relief at ... the ... prices may be,putting the brakes on Americans, summer travel plans, but The ... cards,and a chance to win an all-expense paid vacation., Light The ...
Cached Medicine News:Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:US-Israeli-Palestinian collaboration to advance Alzheimer's disease research 2Health News:Foundation Radiology Group and Cherry Tree Medical Associates Sign Multi-Year Contract for Diagnostic Services 2Health News:SouthWest Benefits Association Elects New Board of Directors 2Health News:Abortion drug's off-label use may have led to deaths 2Health News:Abortion drug's off-label use may have led to deaths 3Health News:Get Free Gas and Help Save a Life 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: